Value through Innovation27 February 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive


Phase III data show significant reductions in blood glucose with investigational compound empagliflozin used as monotherapy in adults with Type 2 Diabetes

- For Non-US and Non-UK Media

New long-term data reinforce safety profile of Pradaxa® for stroke prevention in AF

- For media outside of the US, the UK & Canada only

Boehringer Ingelheim’s investigational all-oral interferon-free combination achieved 95% viral cure rates in genotype-1b hepatitis C patients

- For media outside USA, UK and Canada only

Boehringer Ingelheim and Eli Lilly and Company Alliance to Feature 34 Presentations in Type 1 and Type 2 Diabetes at the 73rd American Diabetes Association® Scientific Sessions

- Ex US & UK Medical Media Only

Boehringer Ingelheim’s investigational faldaprevir+ achieved viral cure in 88% of treatment-naïve hepatitis C patients in Asia

- For media outside USA, UK and Canada only

Boehringer Ingelheim pioneers biopharmaceuticals move to China


LUME-Lung 1: Nintedanib* plus chemotherapy extends the life of lung cancer patients with adenocarcinoma

- For non U.S. Media Only

Superiority of afatinib* over comparator chemotherapy for patients with EGFR mutation-positive advanced lung cancer is reinforced by second Phase III study

- For non U.S. Media Only

New European survey highlights ischaemic stroke protection as treatment priority for patients with atrial fibrillation

- Not intended for media in the UK, the US or Canada

Boehringer Ingelheim and Eli Lilly & Company launch type 2 diabetes educational game, "Complications Combat"

- For Non-U.S. and Non-UK media

Boehringer Ingelheim responds to FDA warning letter


Wireless Pill Bottle Wins Healthcare Innovation World Cup


Phase III results: tiotropium* Respimat® effective in symptomatic asthma patients despite at least ICS†/LABA‡ independent of their age, allergic status, smoking status and bronchodilator response

- For Media outside the U.S., Canada and UK

Change in the Board of Managing Directors at Boehringer Ingelheim


ASCO 2013: Boehringer Ingelheim to present highly anticipated new Phase III results for front-runner compounds afatinib* and nintedanib* in first- and second-line NSCLC treatment


ASCO 2013: New Phase III data reveal targeted treatment with afatinib* or with nintedanib* improves progression-free survival in patients with advanced NSCLC

- For non U.S. Media Only

Boehringer Ingelheim joins Structural Genomics Consortium - for further research into uncurable diseases


Boehringer Ingelheim Announces a Strong 2012 Performance in China